Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Telaprevir's Hidden Talents: New Data Show Effectiveness In Difficult To Cure Populations

This article was originally published in The Pink Sheet Daily

Executive Summary

Treatment-naïve African Americans, Hispanics and patients with liver scarring all had surprisingly better results when the direct-acting antiviral was added to their regimen, Vertex reports.

You may also be interested in...



Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients

About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.

Boceprevir Hep C Response-Guided Therapy Works For Experienced Patients

About half of experienced patients made enough progress to get into the shortened therapy group, and among them the cure rate was 86%.

Third Telaprevir Pivotal Study Raises Bar For Competitors Another Notch

Collective top-line data from the Phase III program testing Vertex Pharmaceuticals' protease inhibitor telaprevir in treatment-naïve and treatment-experienced hepatitis C patients set a high bar for competitors, particularly for Merck & Co.'s boceprevir, with which telaprevir is dueling to be the first approved specifically targeted antiviral therapy for hepatitis C (STAT-C).

Related Content

Topics

UsernamePublicRestriction

Register

PS071383

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel